People who rely on insulin to manage diabetes care deserve affordable access, but systemic barriers stand in the way. Through significant investments in research and solutions that offer more affordable options, we’re working to help.

In 2020, we launched the Lilly Insulin Value Program—allowing anyone eligible to purchase their monthly prescription of Lilly insulin for $35 or less. Now, we’re announcing updates that make accessing $35-a-month* Lilly insulin even easier, including:

• An automatic $35 max out-of-pocket monthly cost for people with commercial insurance at the majority of retail pharmacies

• An easy-to-download savings card that provides a $35 max out-of-pocket monthly cost for people who are uninsured, or need to use a non-participating retail pharmacy

Those who need a savings card can visit our Insulin Value Program site, answer two questions, and immediately download it.

Beyond the changes listed above, we've also made significant price reductions to our branded and non-branded insulins.

*Terms and conditions apply. Automatically applied at the majority of retail pharmacies for those with commercial insurance. Government restrictions exclude people enrolled in federal government insurance programs from Lilly's $35 solutions. But federal law provides that Medicare Part D beneficiaries also pay no more than $35 per month for insulin.

No one should have to make trade-offs when it comes to health. For 100 years, we’ve been focused on addressing the impact of diabetes and improving the lives of people managing the disease. In our recent history, we’ve introduced options that are widely used and have helped with insulin health care costs:

• In 2016, we launched the first follow-on biologic insulin in the U.S.

• In 2019, we introduced our non-branded version of our most popular insulin at a list price 50% lower than its branded counterpart and then lowered the price by an additional 40% in 2022

• In 2020, we created the Lilly Insulin Value Program, enabling the uninsured and commercially insured access to $35 Lilly insulin

• In 2021, we committed all our insulins to the Medicare Part D Savings Model, expanding $35 access even further

But our work to find better ways to support people living with diabetes goes beyond insulin pricing. We’re constantly in search of the next scientific breakthrough—the innovation that will uncover new and better treatments or even, one day, eliminate this disease.